A Phase 3 interventional study of linagliptin and glimepiride in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 613 sites in 43 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-01-07.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies testing linagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Linagliptin · Diabetes Mellitus, Type 2.
Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, this one is the 2nd largest by enrollment, is one of 8 that started in 2010, is one of 31 in phase 3, and was the 24th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 67 studies testing linagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:
Bahria University · Sites in Pakistan
Ages 30–55
By country, each count listing its studies:
Linagliptin: first FDA approval 2011 (TRADJENTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 8 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6,103 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 175 across the 67 interventional studies. Of the 60 that completed or were terminated, 41 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 67 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim: 2 open now, 3 under way, 2 of them phase 3. Of 125 finished, 109 (87%) have results posted.
Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one is the 4th largest by enrollment of the 96 interventional ones that give a count, is one of 18 that started in 2010, is one of 50 in phase 3, and was the 46th registered.
Boehringer Ingelheim’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Among Boehringer Ingelheim’s 130 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to investigate the longterm impact on cardiovascular morbidity and mortality, relevant efficacy parameters (e.g., glycaemic parameters) and safety (e.g., weight and hypoglycaemia) of treatment with linagliptin in patients with type 2 diabetes at elevated cardiovascular risk receiving usual care, and compare outcome against glimepiride.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patient to receive linagliptin or glimepiride placebo over encapsulated tablet Quaque die (QD)
Drug: linagliptin · Drug: glimepiride placebo
patient to receive glimepiride 1-4 mg or linagliptin placebo tablet Quaque die (QD)
Drug: glimepiride · Drug: linagliptin placebo
linagliptin tablets 5mg QD
glimepiride over-encapsulated tablet 1-4 mg QD
linagliptin placebo
glimepiride placebo
The First 3-point Major Adverse Cardiovascular Events (3P-MACE)
The first occurrence of any of the following Clinical Event Committee (CEC) confirmed adjudicated components of the primary composite endpoint: CV death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI (excluding silent MI), or nonfatal stroke is presented.
Time frame: From randomization until individual day of trial completion, up to 432 weeks
The First 4-point (4P)- MACE
The first key secondary endpoint was time to first occurrence of any of the following adjudicated components of the composite endpoint: CV death (including fatal stroke and fatal MI), non-fatal stroke, non-fatal MI (excluding silent MI), or hospitalisation for unstable angina pectoris.
Time frame: From randomization until individual day of trial completion, up to 432 weeks
Percentage of Participants Taking Trial Medication at Trial End, Maintained Glycaemic Control (HbA1c ≤7.0%) Without Need for Rescue Medication, Without >2% Weight Gain, and Without Moderate/Severe Hypoglycaemic Episodes During Maintenance Phase
The second key secondary endpoint was a composite endpoint of treatment sustainability, defined as the percentage of patients taking trial medication at trial end, maintained glycaemic control (HbA1c ≤7.0%) without need for rescue medication, without \>2% weight gain, and without moderate/severe hypoglycaemic episodes during maintenance phase.
Time frame: From Visit 6 (Week 16) to Final visit (Week 432) (Maintenance Phase)
Percentage of Participants Who Were on Trial Medication at Trial End, Maintained Glycaemic Control (HbA1c ≤7.0%) Without Need for Rescue Medication, and Without >2% Weight Gain During Maintenance Phase
The third key secondary endpoint was a composite endpoint of treatment sustainability, defined as percentage of patients who were on trial medication at trial end, maintained glycaemic control (HbA1c ≤7.0%) without need for rescue medication, and without \>2% weight gain during maintenance phase.
Time frame: From Visit 6 (Week 16) to Final visit (Week 432) (Maintenance Phase)
Percentage of Participants With the Occurrence of at Least One Event of 3P-MACE
Percentage of participants occurrence of at least one of the following adjudicated components of CV death (including fatal stroke and fatal MI), non-fatal MI (excluding silent MI) and non-fatal stroke is presented as secondary CV endpoint.
Time frame: From randomization until individual day of trial completion, up to 432 weeks
Percentage of Participants With the Occurrence of at Least One Event of 4P -MACE
Percentage of participants occurrence of at least one of the following adjudicated components of CV death (including fatal stroke and fatal MI), non-fatal MI (excluding silent MI), non-fatal stroke, and hospitalisation for unstable angina pectoris is presented as secondary CV endpoint.
Time frame: From randomization until individual day of trial completion, up to 432 weeks
Percentage of Participants With Occurrence of Any of the Components of the Composite Endpoint of All Adjudication-confirmed Events
Percentage of participants with occurrence of any of the following components of the composite endpoint of all adjudication-confirmed events of: * CV death (including fatal stroke and fatal MI) * non-fatal MI * non-fatal stroke * hospitalisation for unstable angina pectoris * TIA * hospitalisation for heart failure * hospitalisation for coronary revascularisation procedures (CABG, PCI)
Time frame: From start of the treatment until 7 days after the end of treatment, up to 433 weeks
Time to First Occurrence of Any of the Components of the Composite Endpoint of All Adjudication-confirmed Events
Time to first occurrence of any of the following components of the composite endpoint of all adjudication-confirmed events of: * CV death (including fatal stroke and fatal MI) * non-fatal MI * non-fatal stroke * hospitalisation for unstable angina pectoris * Transient ischaemic attack (TIA) * hospitalisation for heart failure * hospitalisation for coronary revascularisation procedures (CABG, PCI)
Time frame: From start of the treatment until 7 days after the end of treatment, up to 433 weeks
Change From Baseline to Final Visit in Hemoglobin A1c (HbA1c)
Change from baseline to final visit in HbA1c is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.
Time frame: Baseline and week 432
Change From Baseline to Final Visit in Fasting Plasma Glucose (FPG)
Change from baseline to final visit in fasting plasma glucose (FPG) is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.
Time frame: Baseline and week 432
Change From Baseline to Final Visit Fasting Total Cholesterol, Low-density Lipoprotein (LDL) Cholesterol and High-density Lipoprotein (HDL) Cholesterol
Change from baseline to final visit in total cholesterol, low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.
Time frame: Baseline and week 432
Change From Baseline to Final Visit in Triglycerides
Change from baseline to final visit in triglycerides is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.
Time frame: Baseline and week 432
Change From Baseline to Final Visit in Creatinine
Change from baseline to final visit in creatinine is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.
Time frame: Baseline and week 432
Change From Baseline to Final Visit in Estimated Glomerular Filtration Rate (eGFR)
Change from baseline to final visit in eGFR is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.
Time frame: Baseline and week 432
Change From Baseline to Final Visit in Urine Albumin Creatinine Ratio (UACR)
Change from baseline to final visit in UACR is presented as secondary diabetes-related endpoint. Least square mean is adjusted geometric mean (gMean) ratio. The Final Visit value referred to the last value obtained on-treatment.
Time frame: Baseline and week 432
Percentage of Participants With Transition in Albuminuria Classes
Percentage of patients with transition in albuminuria classes is presented as secondary endpoint. Data for last value on treatment (LVOT) to baseline (base) is presented.
Time frame: Baseline and week 432
Change From Baseline of Insulin Secretion Rate (ISR) at Fixed Glucose Concentration at 208 Weeks
The endpoint change from baseline of ISR at fixed glucose concentration at 208 weeks as derived from a 3-hour meal tolerance test is Beta-cell function sub-study endpoint.
Time frame: Baseline and week 208
Percentage of Participants With Occurrence of Accelerated Cognitive Decline at End of Follow-up
Occurrence of accelerated cognitive decline based on regression based index (RBI) score at end of follow-up (a dichotomous outcome measure; presence or absence of accelerated cognitive decline) is Cognition sub-study endpoint.
Time frame: 433 weeks
Continuous Glucose Monitoring (CGM) Sub-study: Change From Baseline in the Inter-quartile Range of Diurnal Glucose Variability (Milligrams/ Deciliter) to End of Study
Baseline data for the continuous glucose monitoring sub-study was collected and analyzed. However, the participant number was far less than original planned. The study was stopped early around week 64 (V9) due to recruitment issues and data were not pre-specified to be analyzed and reported at week 64 time point as target was with an estimated time point of 432 weeks for primary or secondary end points. Thus this endpoint was not analysed and only the baseline data collected were analysed and the results are reported in this CGM substudy endpoint.
Time frame: Baseline
CGM Sub-study : Change From Baseline in the Inter-quartile Range of Diurnal Glucose Variability (Millimoles/ Litre) to End of Study
Baseline data for the continuous glucose monitoring sub-study was collected and analyzed. However, the participant number was far less than original planned. The study was stopped early around week 64 (V9) due to recruitment issues and data were not pre-specified to be analyzed and reported at week 64 time point as target was with an estimated time point of 432 weeks for primary or secondary end points. Thus this endpoint was not analysed and only the baseline data collected were analysed and the results are reported in this CGM substudy endpoint.
Time frame: Baseline
This multicentre, multinational, randomised, double-blind, double-dummy, parallel group,comparator-controlled trial compared Linagliptin versus (vs.) Glimepiride, predominantly on metformin background treatment in participants with type 2 diabetes mellitus (T2DM) at elevated cardiovascular (CV) risk receiving usual care.
| Milestone | Linagliptin | Glimepiride |
|---|---|---|
| Started | 3028 | 3014 |
| Patient died (other cause than cv death) | 123 | 146 |
| Treated | 3023 | 3010 |
| Completed | 2899 | 2895 |
| Not completed | 129 | 119 |
| Withdrew: Consent withdrawn (status alive) | 49 | 37 |
| Withdrew: Consent withdrawn (status unknown) | 14 | 12 |
| Withdrew: Site closure (status alive) | 15 | 22 |
| Withdrew: Site closure (status unknown) | 0 | 1 |
| Withdrew: Losttofollowupfor3p-mace(statusalive) | 38 | 35 |
| Withdrew: Losttofollowupfor3p-mace(statusunknown) | 8 | 8 |
| Withdrew: Not treated | 5 | 4 |
| Milestone | Linagliptin | Glimepiride |
|---|---|---|
| Started | 3028 | 3014 |
| Treated | 3023 | 3010 |
| Completed | 1896 | 1832 |
| Not completed | 1132 | 1182 |
| Withdrew: Not treated | 5 | 4 |
| Withdrew: Adverse event | 457 | 523 |
| Withdrew: Lack of efficacy | 61 | 41 |
| Withdrew: Protocol violation | 46 | 47 |
| Withdrew: Lost to follow-up | 24 | 28 |
| Withdrew: Withdrawal by subject | 309 | 328 |
| Withdrew: Other than listed above | 230 | 211 |
The first occurrence of any of the following Clinical Event Committee (CEC) confirmed adjudicated components of the primary composite endpoint: CV death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI (excluding silent MI), or nonfatal stroke is presented.
| Events/ 1000 patients-years | Linagliptin | Glimepiride |
|---|---|---|
| The First 3-point Major Adverse Cardiovascular Events (3P-MACE) | 20.7 | 21.2 |
The first key secondary endpoint was time to first occurrence of any of the following adjudicated components of the composite endpoint: CV death (including fatal stroke and fatal MI), non-fatal stroke, non-fatal MI (excluding silent MI), or hospitalisation for unstable angina pectoris.
| Events/ 1000 patients-years | Linagliptin | Glimepiride |
|---|---|---|
| The First 4-point (4P)- MACE | 23.4 | 23.7 |
The second key secondary endpoint was a composite endpoint of treatment sustainability, defined as the percentage of patients taking trial medication at trial end, maintained glycaemic control (HbA1c ≤7.0%) without need for rescue medication, without \>2% weight gain, and without moderate/severe hypoglycaemic episodes during maintenance phase.
| Percentage of participants (%) | Linagliptin | Glimepiride |
|---|---|---|
| Percentage of Participants Taking Trial Medication at Trial End, Maintained Glycaemic Control (HbA1c ≤7.0%) Without Need for Rescue Medication, Without >2% Weight Gain, and Without Moderate/Severe Hypoglycaemic Episodes During Maintenance Phase | 16.0 (14.7 to 17.3) | 10.2 (9.1 to 11.3) |
The third key secondary endpoint was a composite endpoint of treatment sustainability, defined as percentage of patients who were on trial medication at trial end, maintained glycaemic control (HbA1c ≤7.0%) without need for rescue medication, and without \>2% weight gain during maintenance phase.
| Percentage of participants (%) | Linagliptin | Glimepiride |
|---|---|---|
| Percentage of Participants Who Were on Trial Medication at Trial End, Maintained Glycaemic Control (HbA1c ≤7.0%) Without Need for Rescue Medication, and Without >2% Weight Gain During Maintenance Phase | 17.4 (16.1 to 18.8) | 14.1 (12.9 to 15.4) |
Percentage of participants occurrence of at least one of the following adjudicated components of CV death (including fatal stroke and fatal MI), non-fatal MI (excluding silent MI) and non-fatal stroke is presented as secondary CV endpoint.
| Percentage of participants (%) | Linagliptin | Glimepiride |
|---|---|---|
| Percentage of Participants With the Occurrence of at Least One Event of 3P-MACE | 11.8 (10.7 to 13.0) | 12.0 (10.9 to 13.2) |
Percentage of participants occurrence of at least one of the following adjudicated components of CV death (including fatal stroke and fatal MI), non-fatal MI (excluding silent MI), non-fatal stroke, and hospitalisation for unstable angina pectoris is presented as secondary CV endpoint.
| Percentage of participants (%) | Linagliptin | Glimepiride |
|---|---|---|
| Percentage of Participants With the Occurrence of at Least One Event of 4P -MACE | 13.2 (12.0 to 14.4) | 13.3 (12.2 to 14.6) |
Percentage of participants with occurrence of any of the following components of the composite endpoint of all adjudication-confirmed events of: * CV death (including fatal stroke and fatal MI) * non-fatal MI * non-fatal stroke * hospitalisation for unstable angina pectoris * TIA * hospitalisation for heart failure * hospitalisation for coronary revascularisation procedures (CABG, PCI)
| Percentage of participants (%) | Linagliptin | Glimepiride |
|---|---|---|
| Percentage of Participants With Occurrence of Any of the Components of the Composite Endpoint of All Adjudication-confirmed Events | 17.1 (15.8 to 18.5) | 17.8 (16.4 to 19.2) |
Time to first occurrence of any of the following components of the composite endpoint of all adjudication-confirmed events of: * CV death (including fatal stroke and fatal MI) * non-fatal MI * non-fatal stroke * hospitalisation for unstable angina pectoris * Transient ischaemic attack (TIA) * hospitalisation for heart failure * hospitalisation for coronary revascularisation procedures (CABG, PCI)
| Events/ 1000 patients-years | Linagliptin | Glimepiride |
|---|---|---|
| Time to First Occurrence of Any of the Components of the Composite Endpoint of All Adjudication-confirmed Events | 31.1 | 32.4 |
Change from baseline to final visit in HbA1c is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.
| Percentage glycosylated hemoglobin (%) | Linagliptin | Glimepiride |
|---|---|---|
| Change From Baseline to Final Visit in Hemoglobin A1c (HbA1c) | 0.06 ± 0.02 | 0.15 ± 0.02 |
Change from baseline to final visit in fasting plasma glucose (FPG) is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.
| Milligram/ deciliter (mg/dL) | Linagliptin | Glimepiride |
|---|---|---|
| Change From Baseline to Final Visit in Fasting Plasma Glucose (FPG) | 12.4 ± 0.9 | 19.7 ± 0.9 |
Change from baseline to final visit in total cholesterol, low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.
| mg/dL | Linagliptin | Glimepiride |
|---|---|---|
| LDL cholesterol | -6.1 ± 0.6 | -6.5 ± 0.6 |
| HDL cholesterol | 0.7 ± 0.2 | 0.3 ± 0.2 |
| Total cholesterol | -5.4 ± 0.7 | -0.5 ± 0.7 |
Change from baseline to final visit in triglycerides is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.
| mg/dL | Linagliptin | Glimepiride |
|---|---|---|
| Change From Baseline to Final Visit in Triglycerides | 1.7 ± 2.2 | 5.2 ± 2.2 |
Change from baseline to final visit in creatinine is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.
| mg/dL | Linagliptin | Glimepiride |
|---|---|---|
| Change From Baseline to Final Visit in Creatinine | 0.08 ± 0.01 | 0.09 ± 0.01 |
Change from baseline to final visit in eGFR is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment.
| mL/minute/1.73 meter^2 | Linagliptin | Glimepiride |
|---|---|---|
| Change From Baseline to Final Visit in Estimated Glomerular Filtration Rate (eGFR) | -4.0 ± 0.3 | -5.0 ± 0.3 |
Change from baseline to final visit in UACR is presented as secondary diabetes-related endpoint. Least square mean is adjusted geometric mean (gMean) ratio. The Final Visit value referred to the last value obtained on-treatment.
| mg/ gcrea | Linagliptin | Glimepiride |
|---|---|---|
| Change From Baseline to Final Visit in Urine Albumin Creatinine Ratio (UACR) | 1.52 ± 1.83 | 1.57 ± 1.83 |
Percentage of patients with transition in albuminuria classes is presented as secondary endpoint. Data for last value on treatment (LVOT) to baseline (base) is presented.
| Percentage of participants (%) | Linagliptin | Glimepiride |
|---|---|---|
| Base (<30mg/gcrea) LVOT (<30mg/gcrea) | 58.4 | 57.7 |
| Base(<30mg/gcrea)LVOT(>=30 to<=300mg/gcrea) | 14.1 | 16.0 |
| Base (<30 mg/gcrea) LVOT (>300 mg/gcrea) | 1.4 | 1.4 |
| Base (>=30 to <=300 mg/gcrea) LVOT(<30mg/gcrea) | 5.4 | 5.1 |
| Base(>=30to<=300mg/gcrea)LVOT(>=30to<=300mg/gcrea) | 12.7 | 12.1 |
| Base (>=30 to <=300 mg/gcrea) LVOT(>300 mg/gcrea) | 3.5 | 3.7 |
| Base (>300 mg/gcrea) LVOT (<30 mg/gcrea) | 0.1 | 0.3 |
| Base (>300 mg/gcrea) LVOT(>=30 to<=300mg/gcrea) | 0.8 | 0.9 |
| Base (>300 mg/gcrea) LVOT(>300 mg/gcrea) | 3.4 | 2.7 |
The endpoint change from baseline of ISR at fixed glucose concentration at 208 weeks as derived from a 3-hour meal tolerance test is Beta-cell function sub-study endpoint.
| Picomol/ minute/meter^2 (pmol/min/m²) | Linagliptin | Glimepiride |
|---|---|---|
| Change From Baseline of Insulin Secretion Rate (ISR) at Fixed Glucose Concentration at 208 Weeks | 11.07 ± 15.07 | 6.95 ± 13.76 |
Occurrence of accelerated cognitive decline based on regression based index (RBI) score at end of follow-up (a dichotomous outcome measure; presence or absence of accelerated cognitive decline) is Cognition sub-study endpoint.
| Percentage of participants (%) | Linagliptin | Glimepiride |
|---|---|---|
| Percentage of Participants With Occurrence of Accelerated Cognitive Decline at End of Follow-up | 27.8 (25.6 to 30.0) | 27.6 (25.4 to 29.9) |
Baseline data for the continuous glucose monitoring sub-study was collected and analyzed. However, the participant number was far less than original planned. The study was stopped early around week 64 (V9) due to recruitment issues and data were not pre-specified to be analyzed and reported at week 64 time point as target was with an estimated time point of 432 weeks for primary or secondary end points. Thus this endpoint was not analysed and only the baseline data collected were analysed and the results are reported in this CGM substudy endpoint.
| Milligrams/ deciliter (mg/ dL) | All Participants |
|---|---|
| Continuous Glucose Monitoring (CGM) Sub-study: Change From Baseline in the Inter-quartile Range of Diurnal Glucose Variability (Milligrams/ Deciliter) to End of Study | 44.2 ± 12.6 |
Baseline data for the continuous glucose monitoring sub-study was collected and analyzed. However, the participant number was far less than original planned. The study was stopped early around week 64 (V9) due to recruitment issues and data were not pre-specified to be analyzed and reported at week 64 time point as target was with an estimated time point of 432 weeks for primary or secondary end points. Thus this endpoint was not analysed and only the baseline data collected were analysed and the results are reported in this CGM substudy endpoint.
| Millimoles/ Litre (mmol/L) | All Participants |
|---|---|
| CGM Sub-study : Change From Baseline in the Inter-quartile Range of Diurnal Glucose Variability (Millimoles/ Litre) to End of Study | 2.45 ± 0.7 |
Collected over From start of the treatment until 7 days after the end of treatment, up to 433 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Linagliptin | 308/3,023 (10.2%) | 1,403/3,023 (46.4%) | 2,376/3,023 (78.6%) |
| Glimepiride | 336/3,010 (11.2%) | 1,448/3,010 (48.1%) | 2,504/3,010 (83.2%) |
| Event | Linagliptin | Glimepiride |
|---|---|---|
| PneumoniaInfections and infestations | 83/3023 | 83/3010 |
| Angina unstableCardiac disorders | 54/3023 | 65/3010 |
| Myocardial infarctionCardiac disorders | 49/3023 | 64/3010 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 49/3023 | 63/3010 |
| Cerebrovascular accidentNervous system disorders | 51/3023 | 61/3010 |
| Cardiac failureCardiac disorders | 58/3023 | 53/3010 |
| Acute myocardial infarctionCardiac disorders | 52/3023 | 56/3010 |
| Chest painGeneral disorders | 50/3023 | 52/3010 |
| Atrial fibrillationCardiac disorders | 39/3023 | 48/3010 |
| Acute kidney injuryRenal and urinary disorders | 47/3023 | 41/3010 |
| Event | Linagliptin | Glimepiride |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 299/3023 | 1067/3010 |
| NasopharyngitisInfections and infestations | 530/3023 | 517/3010 |
| HyperglycaemiaMetabolism and nutrition disorders | 422/3023 | 483/3010 |
| HypertensionVascular disorders | 430/3023 | 452/3010 |
| Back painMusculoskeletal and connective tissue disorders | 388/3023 | 368/3010 |
| DiarrhoeaGastrointestinal disorders | 365/3023 | 324/3010 |
| DizzinessNervous system disorders | 283/3023 | 358/3010 |
| BronchitisInfections and infestations | 315/3023 | 340/3010 |
| Upper respiratory tract infectionInfections and infestations | 313/3023 | 319/3010 |
| Urinary tract infectionInfections and infestations | 318/3023 | 312/3010 |
Treated set (TS): All patients treated with at least one dose of trial drug.
| Age, Continuous(Years) | Linagliptin | Glimepiride | Total |
|---|---|---|---|
| Mean | 63.9 ± 9.5 | 64.2 ± 9.5 | 64.0 ± 9.5 |
| Sex: Female, Male(Participants) | Linagliptin | Glimepiride | Total |
|---|---|---|---|
| Female | 1185 | 1229 | 2414 |
| Male | 1838 | 1781 | 3619 |
| Ethnicity (NIH/OMB)(Participants) | Linagliptin | Glimepiride | Total |
|---|---|---|---|
| Hispanic or Latino | 519 | 513 | 1032 |
| Not Hispanic or Latino | 2495 | 2487 | 4982 |
| Unknown or Not Reported | 9 | 10 | 19 |
| Race (NIH/OMB)(Participants) | Linagliptin | Glimepiride | Total |
|---|---|---|---|
| American Indian or Alaska Native | 106 | 108 | 214 |
| Asian | 531 | 530 | 1061 |
| Native Hawaiian or Other Pacific Islander | 5 | 3 | 8 |
| Black or African American | 155 | 169 | 324 |
| White | 2217 | 2190 | 4407 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 9 | 10 | 19 |
Showing the first 100 of 613 sites across 43 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2010 to primary completion in Aug 2018, 93 months.
Results were first posted in Jan 2020, 1 year 4 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 93 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linagliptin